• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Invivyd, Inc. - Common Stock (NQ:IVVD)

    2.205 -0.035 (-1.56%)
    Streaming Delayed Price Updated: 3:53 PM EST, Jan 21, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Invivyd, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 Next >
    News headline image
    Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026
    From Invivyd
    Via GlobeNewswire
    News headline image
    Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights
    From Invivyd
    Via GlobeNewswire
    News headline image
    Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
    From Invivyd
    Via GlobeNewswire
    News headline image
    Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
    From Invivyd
    Via GlobeNewswire
    News headline image
    Invivyd to Participate at the 8th Annual Evercore Healthcare Conference
    From Invivyd
    Via GlobeNewswire
    News headline image
    Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness
    From Invivyd
    Via GlobeNewswire
    News headline image
    Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants
    From Invivyd
    Via GlobeNewswire
    News headline image
    Invivyd Announces Proposed Public Offering of Common Stock
    From Invivyd
    Via GlobeNewswire
    News headline image
    Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights
    From Invivyd
    Via GlobeNewswire
    News headline image
    Invivyd to Host Third Quarter 2025 Financial Results and Corporate Update Call on November 6, 2025
    From Invivyd
    Via GlobeNewswire
    News headline image
    Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
    From Invivyd
    Via GlobeNewswire
    News headline image
    Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
    From Invivyd
    Via GlobeNewswire
    News headline image
    Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors
    From Invivyd
    Via GlobeNewswire
    News headline image
    Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer
    From Invivyd
    Via GlobeNewswire
    News headline image
    SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd’s VYD2311 At RECOVER-TLC Workshop September 9-10, 2025
    From Invivyd
    Via GlobeNewswire
    News headline image
    Invivyd to Participate in Upcoming Investor Conferences
    From Invivyd
    Via GlobeNewswire
    News headline image
    Power Metallic’s (TSX-V: PNPN | OTCQB: PNPNF) Strategic Appointment Signals Major Paradigm Shift Ahead – More Stocks Inside
    Via AB Newswire
    Topics Government
    News headline image
    Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter’s Option to Purchase Additional Shares
    From Invivyd
    Via GlobeNewswire
    News headline image
    Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants
    From Invivyd
    Via GlobeNewswire
    News headline image
    Invivyd Announces Proposed Public Offering of Common Stock
    From Invivyd
    Via GlobeNewswire
    News headline image
    Invivyd Announces Continued Neutralizing Activity of PEMGARDA® (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG (“Stratus”)
    From Invivyd
    Via GlobeNewswire
    News headline image
    Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights
    From Invivyd
    Via GlobeNewswire
    News headline image
    Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19
    From Invivyd
    Via GlobeNewswire
    News headline image
    Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome
    From Invivyd
    Via GlobeNewswire
    News headline image
    National Comprehensive Cancer Network® (NCCN®) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published in JAMA Oncology Underscore Severe Impact of COVID-19 on This Population
    From Invivyd
    Via GlobeNewswire
    News headline image
    Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection
    From Invivyd
    Via GlobeNewswire
    News headline image
    Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2
    From Invivyd
    Via GlobeNewswire
    News headline image
    Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome
    From Invivyd
    Via GlobeNewswire
    News headline image
    Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas
    From Invivyd
    Via GlobeNewswire
    News headline image
    Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19
    From Invivyd
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.